Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population-based study and meta-analysis

被引:2
作者
van Der Kruijssen, Dave E. W. [1 ]
van Der Kuil, Auke J. S. [1 ]
Vink, Geraldine R. [1 ,2 ]
Punt, Cornelis J. A. [3 ]
de Wilt, Johannes H. W. [4 ]
Elias, Sjoerd G. [3 ]
Koopman, Miriam [1 ]
机构
[1] Univ Med Ctr Utrecht, Utrecht Univ, Dept Med Oncol, Utrecht, Netherlands
[2] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Utrecht Univ, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Dept Surg, Nijmegen, Netherlands
关键词
metastatic colorectal cancer; primary tumor location; prognostic value; FOLFOXIRI PLUS BEVACIZUMAB; MAINTENANCE TREATMENT; COLON-CANCER; LOCATION; CHEMOTHERAPY; 1ST-LINE; CAPECITABINE; OXALIPLATIN; COMBINATION; CONTINUUM;
D O I
10.1002/ijc.34347
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We studied the prognostic value of primary tumor sidedness in metastatic colorectal cancer over time and across treatment lines. Population data on synchronous metastatic colorectal cancer patients were extracted from the Netherlands Cancer Registry and SEER database. Pubmed, EMBASE and Cochrane library were searched for prospective studies on metastatic colorectal cancer to conduct a meta-analysis. Inclusion criteria consisted of metastatic disease, systemic treatment with palliative intent and specification of primary tumor location. Data were pooled using a random-effects model. For the population-based data, multivariable Cox models were constructed. The Grambsch-Therneau test was conducted to evaluate the potential time-varying nature of sidedness. Meta-regression incorporating treatment-line as variable was conducted to test the pre-specified hypothesis that the prognostic value of sidedness varies over time. Analysis of 12 885 and 16 160 synchronous metastatic colorectal cancer patients registered in the Netherlands Cancer Registry and SEER database, respectively, indicated a time-varying prognostic value of sidedness (P < .01). Thirty-one studies were selected for the meta-analysis (9558 patients for overall survival analysis). Pooled univariable hazard ratio(left-sided/right-sided) for overall survival was 0.71 (95% CI: 0.65-0.76) in 1st-line, 0.76 (0.54-1.06) in 2nd-line and 1.01 (0.86-1.19) in 3rd-line studies. Hazard ratios were significantly influenced by treatment line (P = .035). The prognostic value of sidedness of the primary tumor in metastatic colorectal cancer patients treated with palliative systemic therapy decreases over time since diagnosis, suggesting that sidedness may not be a useful stratification factor in late-line trials. This decrease in prognostic value should be taken into account when providing prognostic information to patients.
引用
收藏
页码:1360 / 1369
页数:10
相关论文
共 52 条
[1]   FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNu-1 trial [J].
Aranda, Enrique ;
Maria Vieitez, Jose ;
Gomez-Espana, Auxiliadora ;
Gil Calle, Silvia ;
Salud-Salvia, Antonieta ;
Grana, Begona ;
Garcia-Alfonso, Pilar ;
Rivera, Fernando ;
Alfonso Quintero-Aldana, Guillermo ;
Jose Reina-Zoilo, Juan ;
Gonzalez-Flores, Encarnacion ;
Salgado Fernandez, Mercedes ;
Guillen-Ponce, Carmen ;
Garcia-Carbonero, Rocio ;
Jose Safont, Maria ;
La Casta Munoa, Adelaida ;
Garcia-Paredes, Beatriz ;
Lopez Lopez, Rafael ;
Sastre, Javier ;
Diaz-Rubio, Eduardo .
ESMO OPEN, 2020, 5 (06)
[2]   Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness [J].
Bencsikova, Beatrix ;
Budinska, Eva ;
Selingerova, Iveta ;
Pilatova, Katerina ;
Fedorova, Lenka ;
Greplova, Kristina ;
Nenutil, Rudolf ;
Valik, Dalibor ;
Obermannova, Radka ;
Sheard, Michael A. ;
Zdrazilova-Dubska, Lenka .
BMC CANCER, 2019, 19 (1)
[3]   Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies [J].
Boeckx, N. ;
Koukakis, R. ;
de Beeck, K. Op ;
Rolfo, C. ;
Van Camp, G. ;
Siena, S. ;
Tabernero, J. ;
Douillard, J. -Y. ;
Andre, T. ;
Peeters, M. .
ANNALS OF ONCOLOGY, 2017, 28 (08) :1862-1868
[4]   Effect of Primary Tumor Location on Second-or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies [J].
Boeckx, Nele ;
Koukakis, Reija ;
Op de Beeck, Ken ;
Rolfo, Christian ;
Van Camp, Guy ;
Siena, Salvatore ;
Tabernero, Josep ;
Douillard, Jean-Yves ;
Andre, Thierry ;
Peeters, Marc .
CLINICAL COLORECTAL CANCER, 2018, 17 (03) :170-+
[5]   Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 [J].
Brule, S. Y. ;
Jonker, D. J. ;
Karapetis, C. S. ;
O'Callaghan, C. J. ;
Moore, M. J. ;
Wong, R. ;
Tebbutt, N. C. ;
Underhill, Cr. ;
Yip, D. ;
Zalcberg, J. R. ;
Tu, D. ;
Goodwin, R. A. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (11) :1405-1414
[6]  
Colorectal Cancer Alliance, SID MATT LEFT VS RIG
[7]   Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO [J].
Cremolini, C. ;
Antoniotti, C. ;
Lonardi, S. ;
Bergamo, F. ;
Cortesi, E. ;
Tomasello, G. ;
Moretto, R. ;
Ronzoni, M. ;
Racca, P. ;
Loupakis, F. ;
Zaniboni, A. ;
Tonini, G. ;
Buonadonna, A. ;
Marmorino, F. ;
Allegrini, G. ;
Granetto, C. ;
Masi, G. ;
Zagonel, V. ;
Sensi, E. ;
Fontanini, G. ;
Boni, L. ;
Falcone, A. .
ANNALS OF ONCOLOGY, 2018, 29 (07) :1528-1534
[8]   Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial [J].
Cremolini, Chiara ;
Malmorino, Federica ;
Bergamo, Francesca ;
Aprile, Giuseppe ;
Salvatore, Lisa ;
Masi, Gianluca ;
Dell'Aquila, Emanuela ;
Antoniotti, Carlotta ;
Murgioni, Sabina ;
Allegrini, Giacomo ;
Borelli, Beatrice ;
Gemma, Donatello ;
Casagrande, Mariaelena ;
Granetto, Cristina ;
Delfanti, Sara ;
Di Donato, Samantha ;
Schirripa, Marta ;
Sensi, Elisa ;
Tonini, Giuseppe ;
Lonardi, Sara ;
Fontanini, Gabriella ;
Boni, Luca ;
Falcone, Alfredo .
EUROPEAN JOURNAL OF CANCER, 2019, 109 :175-182
[9]   Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer [J].
Denda, Tadamichi ;
Sakai, Daisuke ;
Hamaguchi, Tetsuya ;
Sugimoto, Naotoshi ;
Ura, Takashi ;
Yamazaki, Kentaro ;
Fujii, Hirofumi ;
Kajiwara, Takeshi ;
Nakajima, Takako Eguchi ;
Takahashi, Shin ;
Otsu, Satoshi ;
Komatsu, Yoshito ;
Nagashima, Fumio ;
Moriwaki, Toshikazu ;
Esaki, Taito ;
Sato, Takeo ;
Itabashi, Michio ;
Oki, Eiji ;
Sasaki, Toru ;
Sunaga, Yoshinori ;
Ziti-Ljajic, Samira ;
Brillac, Claire ;
Yoshino, Takayuki .
CANCER SCIENCE, 2019, 110 (03) :1032-1043
[10]   Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study [J].
Ducreux, Michel ;
Petersen, Lone Norgard ;
Oehler, Leopold ;
Bergamo, Francesca ;
Metges, Jean-Philippe ;
de Groot, Jan Willem ;
Wang, Jaw-Yuan ;
Garcia Paredes, Beatriz ;
Dochy, Emmanuelle ;
Fiala-Buskies, Sabine ;
Cervantes, Andres ;
Manuel O'Connor, Juan ;
Falcone, Alfredo .
EUROPEAN JOURNAL OF CANCER, 2019, 123 :146-154